

Skin sensitisation safety assessment without animal testing: A case study



N. Alépée on behalf of Cosmetics Europe's Skin Tolerance Task Force

T. Ashikaga, E. Clouet, M. Cluzel, N. Gellatly, J. Hibatallah, P. Kern, M. Klaric, J. Kuehnl, S. Martinozzi-Teissier, K. Mewes, M. Miyazawa, E. van Vliet, S. Hoffmann, D. Petersohn



Skin Sensitization Risk Assessment without in vivo data

Chemical X is a new cosmetic ingredient.

Challenge: To conduct a risk assessment in the absence of generating new *in vivo* data


Question: Can Chemical X be used safely* at 0.2 % in a

- a) face cream or
- b) shower gel?

*Considering only skin sensitization for this case study



Skin Sensitization Risk Assessment



Risk assessment to **prevent** skin sensitisation in consumers

— What risk does ingredient X at conc. Y in product Z pose to the consumer?

To do so :

- Exposure data product relevant consumer exposure scenario
- Hazard characterisation data dose response information



Hazard identification

What information do we have available right now?

Structural alerts

- In vitro / in chemico / in silico data
- Review of analog data / Read-across



ЮΗ

Structure

Cinnamyl Alcohol (CAS# 104-54-1)

No alerts for skin sensitization based upon o

- Computational tox. tools (e.g. DEREK)
- Expert chemistry judgement (for alcohols)
- Read-across to similar materials (e.g. benzyl alcohol)

However expert chemistry judgement tells us:

Alcohols can be metabolized / oxidized to aldehydes - known for sensitization potential


How do I address metabolism to a reactive material in my risk assessment with *in vitro / in chemico* tools?



=0

Metabolites?

Possible metabolite: Cinnamic aldehyde



Metabolism study confirmed forming of metabolites

Phys chem / Hazard Data comparison

| | MW | Log P | рКа | Solubility (g/l) | Vapour pressure (mm/Hg) |
|-------------------|-----|-------|------|---------------------|-------------------------------|
| Cinnamyl alcohol | 134 | 1.95 | 3.98 | 1.8 | 0.024 |
| Cinnamic aldehyde | 132 | 2.1 | | 1.4-2.1 | 0.03 |

| Chemical | LLNA* | Human class* | DPRA | PPRA | KeratinoSens | Sens-IS | h-CLAT | U-SENS |
|----------------------|--------------|-----------------|--------------------|-----------------------|--------------|---------|----------|----------|
| Cinnamyl alcohol | weak | 3 | positive (low) | Minimal Reactivity | positive | weak | positive | positive |
| Cinnamic aldehyde | moderat e | 2 | Positive (high) | reactive | positive | strong | positive | positive |

irope



Integration of Hazard data

| Case Study approach | BASF 2 of 3 (Bauch et al, 2012) | Shiseido (Tsujita-Inoue et al., 2014) | KAO STS (Takenouchi et al 2015) | KAO ITS (Takenouchi et al 2015) | BN ITS3 (Jaworska et al. 2015) | ICCVAM ITS | L'Oreal ITS |
|------------------------|---------------------------------------|---|---------------------------------------|---------------------------------------|--|---------------|----------------|
| Cinnamic alcohol | positive | moderate | weak | weak | pEC3 category.2 (likely translates into weak) | positive | positive |
| Cinnamic aldehyde | positive | moderate | weak | weak | pEC3 category.3 (likely translates into moderate) | positive | positive |

- All data, individual and combined point towards a skin sensitizer
- No clear conclusion on potency



Key questions for risk assessment?

We can conclude

- X is a skin sensitiser
- threshold approaches not appropriate for face cream, maybe shower gel
- need to derive a potency for use in RA

How confident are we in prediction of the potency?

- Is it weak or moderate
- How confident are we that the tools are not underestimating potency?
- What dose per unit area do I assign if I conclude moderate?
 - 100 µg/cm²?
 - Is it appropriate to apply a Quantitative Risk Assessment (QRA) approach with/without additional uncertainty factors ?



Conclusions

Integrated approaches exist to identify sensitisers (Yes / No)

There is still uncertainty as to how accurate the potency predictions are from existing *in vitro/in chemico* tools

There is uncertainty as to how to translate the output of the *in vitro/ in chemico* tools to a metric for use in risk assessment

Additional uncertainty factors might be required if this data were to be used in a standard QRA approach to skin allergy risk assessment

Evaluation of additional case studies will enable us to begin to address these questions